• Read more about Jeff’s Weight Loss Surgery Success Story

When Jeff's weight started to impact his performances and his health, he turned to Cooper and a team who could help him succeed. Not only was Jeff’s weight affecting his performance, he was beginning to develop serious chronic illnesses

• Read more about EvoPAR-Breast01

Short Title: EvoPAR-Breast01

The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer. 

Participants will be randomised in a 2:2:1 ratio to one of the following intervention groups:

• Arm 1: saruparib (AZD5305) plus camizestrant
• Arm 2: Physician's choice CDK4/6i plus physician's choice ET
• Arm 3: Physician's choice CDK4/6i plus camizestrant Treatment continues until BICR-confirmed disease progression, unacceptable toxicity occurs, or the participant withdraws consent.

Study Number:

EvoPAR-Breast01

Study Status:

Enrolling

Treatment Agent:

Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib, Fulvestrant, Letrozole, Anastrozole, Exemestane

Resources and Links

National Clinical Trial Identified Number: NCT06380751

Disease:

• Advanced Breast Cancer

Study Phase:

III

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Rebecca J. Jaslow, MD

Department:

• Hematology and Medical Oncology

• Read more about GY036

Short Title: GY036

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.

Study Number:

GY036

Study Status:

Enrolling

Treatment Agent:

Bevacizumab, Olaparib

Resources and Links

National Clinical Trial Identified Number: NCT06580314

Disease:

• Fallopian Tube Endometrioid Adenocarcinoma,
• Fallopian Tube High Grade Serous Adenocarcinoma,
• Ovarian Carcinoma,
• Ovarian High Grade Endometrioid Adenocarcinoma,
• Ovarian High Grade Serous Adenocarcinoma,
• Primary Peritoneal Endometrioid Adenocarcinoma,
• Primary Peritoneal High Grade Serous Adenocarcinoma

Study Phase:

III

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• David P. Warshal, MD, FACOG

Department:

• Gynecologic Cancer Center